Wet Age Related Macular Degeneration

Wet AMD occurs when abnormal blood vessels grow under the retina and leak causing vision loss.

What is wet macular degeneration?

Wet macular degeneration occurs when abnormal blood vessels (known as choroidal neovascularization) grow under the macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision. It is called wet because of the fluid the leaks from the abnormal blood vessels. Patient with wet macular degeneration usually develop rapid vision loss over the course of weeks or months. Straight lines may look wavy because the macula is no longer smooth. Below is a discussion of various manifestations of wet AMD. Click the button to learn more about the treament of wet AMD

Treatment of Wet AMD

What is a Choroidal Neovascular membrane?

Choroidal neovascular membranes are new blood vessels that grow beneath the retina and disrupt vision. These blood vessels grow in an area called the choroid, the area between the retina and the sclera (the white part of your eye). The choroid supplies oxygen and nutrients to the eye. These blood vessel growths break through the barrier between the choroid and the retina. Although one would think that more blood vessels supplying nutrients to the eye would be good, it is not. The new blood vessels grow out with scarring. Also, they leak more than normal retinal blood vessels. Finally they can bleed and blood is very harmful to the retina. Rarely patient maintain good vision with choroidal neovascular membranes (about 10 or 20 percent). Most people lose central vision rapidly who develop choroidal neovascular membranes unless they are treated.

What is a Disciform Scar?

Untreated, a person with a choroidal neovascular membrane will usually develop a submacular scar like the one in the photo. The scars are white because the are composed mostly of fibroblasts. Subretinal scars cause degeneration of the overlying retina and loss of vision. The scars are circular or disc shaped and therefore are called disciform scars. They cause vision loss because they block the transport of nutrients from the supporting tissue under the retina (the retinal pigment epithelium) which is vital to the survival and function of the retina. Unfortunately, once the retina has been permanently damaged by a submacular scar it cannot be resurrected. Retinal tissue does not regenerate. It cannot be replaced. Research is being pursued all over the world trying to find a way to fix damaged retinas, but nothing, at the moment (January 2015) is close to being effective.

What is Subretinal Fluid?

A hallmark of wet AMD is subretinal fluid. This comes from leaking abnormal blood vessels under the macula. Their is not a firm attachment between the retina and the underlying retinal pigment epithelium. The retina is held in place against the underlying retinal pigment epithelium by a pump in the retinal pigment epithelium. This pump removes naturally occurring fluid in the subretinal space and keeps it dry. The leakage from a choroidal neovascular membrane overwhelms the natural pump in the retinal pigment epithelium and subretinal fluid accumulates. The subretinal fluid distorts the retina causing patients to see things as wavy instead of straight. It also decreases the supply of oxygen and nutrients to the retina and makes the vision blurry. Subretinal fluid is best dectected using optical coherence tomography. The photo shows a dark area under the retina where subretinal fluid has accumulated. The effect (or lack of effect) of treatments for wet macular degeneration is usually evaluated by monitoring the optical coherence tomography scan for subretinal fluid.

What is a Pigment Epithelial Detachment?

Most patients with wet AMD develop a retinal pigment epithelial detachment. The retinal pigment epithelium is a layer of cells under the retina that supports the retina. In the OCT image it is the bright white line closest to the bottom of the picture with RPE on top of it. (there are two lines, the line on the bottom is the RPE, the line on the top is the back of the retina). When fluid or lipid (fatty material) or blood vessels accumulates under the retinal pigment epithelium the retinal pigment epithelium is pushed up. The bump in the retinal pigment epithelium is called a pigment epithelial detachment. These are common in wet AMD. Treatment does not always cause the retinal pigment epithelial detachment to flatten. Vision can be excellent over a retinal pigment epithelial detachment. The distortion of the overlying retina will often cause distortion in the vision. Retinal pigment epithlial detachments do not compromise the ability of the retinal pigment epithelium to nurish the retina. Finally, you can develop a retinal pigment epithelial detachment without wet AMD. These retinal pigment epithelial detachments have lipid (fatty) material in them but no blood vessels. About 90 percent of retinal pigment epithelial detachments are associated with wet AMD and abnormal blood vessel growth.

What is a Polypoidal Choroidal Vasculopathy (PCV)?

Polypoidal choroidal vasculopathy is a subtype of wet AMD that is caused by a mature vascular complex under the retina. It is characterized by a branching vascular network with one or more polyps at the termini of the vessels. The branching vascular network and the polyp(s) are best seen with indocyanine green angiography. There is some evidence the polypoidal choroidal vasculaopathy (PCV) is less response to anti-VEGF injection therapy than other forms of wet AMD. In many cases photodynamic therapy is helpful in treating PCV.

What is a Submacular Hemorrhage (Blood)?

Submacular hemorrhage (blood) is one of the most feared complications of wet AMD. The blood is toxic to the overlying retina and causes immediate severe vision loss. The photo shows blood in a patient whose vision dropped from 20/30 immediately to 20/1600 (no longer able to see even the big letters on the visual acuity chart). Fortunately, submacular hemorrhage is rare and occurs in only about 1 percent of patient with wet AMD. Once there is a submacular hemorrhage, vision almost never returns to what it was before the bleed. Treatment of wet AMD helps reduce the amount of vision loss. Surgery for submacular hemorrhage is controversial and may not be helpful. Visual recovery in someone with a submacular hemorrhage is very very slow. It usually takes about 6 months for the blood to absorb and then another 6-12 months for the overlying retina to heal. Vision usually improves some as the blood absorbs but not much. Most patients recover enough vision to see the big letters on the visual acuity chart but not enough vision to read.

Wet Macular Degeneration NEWS

Below are current articles from a Google News Feed on Wet Macular Degeneration

VIDEO: Notal Vision pursues home-based OCT for wet AMD monitoring  Healio

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Quinton Oswald, CEO of Notal Vision, discusses the company's pursuit of an OCT home ...

Age-Related Macular Degeneration Drug Combo Scrapped Despite Safe Profile  Specialty Pharmacy Times

Ophthotech Corp. said it won't move forward with further clinical trials of its complement factor C5 inhibitor for the treatment of wet age-related macular ...

Wet Age-Related Macular Degeneration: The European Market and Competitive Landscape (2018-2023) - ResearchAndMarkets.com  Tullahoma News and Guardian

DUBLIN--(BUSINESS WIRE)--Dec 11, 2018--The "Wet Age-Related Macular Degeneration: The European Market and Competitive Landscape (2018-2023)" ...

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy  PRNewswire

BOSTON, Dec. 10, 2018 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat ...

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

Read the bottom line: Eye doctors, Independent Health clash over drug costs  Buffalo News

Retina specialists are seeing red after a major health insurer told them they could be penalized next year if they too often use $2000-a-dose brand name drugs ...

First patient dosed in Adverum wet AMD gene therapy trial  Healio

The first patient has been dosed in a phase 1 trial of ADVM-022 gene therapy for wet age-related macular degeneration, Adverum Biotechnologies announced ...

Wet Age-related Macular Degeneration Pipeline Insights Report - Leading Companies in this Space are Novartis, OHR Pharmaceutical, Allergan and Opthotech - ResearchAndMarkets.com  Odessa American

DUBLIN--(BUSINESS WIRE)--Dec 3, 2018--The "Wet Age-related Macular Degeneration - Pipeline Insights, 2017" drug pipelines has been added to ...

Loma Linda Patient First in California to Receive a Telescope Implant for Macular Degeneration after Having Cataract Surgery  Associated Press

LOMA LINDA, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- A patient at Loma Linda University Eye Institute became the first in California to receive the Miniature ...

Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration  GlobeNewswire

ADVM-022 is the first intravitreally delivered gene therapy utilizing directed evolution AAV.7m8 vector for wet AMD; OPTIC trial to evaluate single administration ...

Opthea completes enrollment in mid-stage study of OPT-302 in wet AMD  Seeking Alpha

Opthea Limited (CKDXY) announces the final enrollment of 366 patients in its Phase 2b clinical trial evaluating OPT-302 for the treatment of wet age-relate.

Zimura/Lucentis Combo Safe, But Company Decides Not to Move Forward  MD Magazine

Ophthotech says it's sidelining its Zimura/Lucentis program despite positive phase 2a results.

Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy  Associated Press

MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting ...

Eye injections are 'magic bullets' for retinal disease  Florida Today

Without these injections, many of these patients would be going blind.

Visual outcome predictors of anti-VEGF therapy in neovascular AMD | Acta Ophthalmologica  MD Linx

Internal Medicine Article: Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial ...

Fewer Injections With New Wet Macular Degeneration Therapies  Medscape

New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, ...

Eye drops could replace injections in a new treatment for sight loss  Lexology

One of the largest known causes of visual disturbance is a condition called age-related macular degeneration (AMD). It is estimated that approximately…

Warning, investors: Way too many drugs will be vying for market share in 15 diseases  FiercePharma

Biopharma knows this industry plague all too well: One company finds a new way to tackle a disease and a whole bunch of rivals pile in. And that overcrowding ...

Top five AAO videos  Healio

At the annual American Academy of Ophthalmology meeting in Chicago, Healio.com/OSN talked with key opinion leaders regarding important ophthalmic ...

VIDEO: Allergan seeks to expand footprint with retinal therapy pipeline  Healio

CHICAGO — At the Ophthalmology Innovation Summit at AAO, Jag Dosanjh, senior vice president of eye care for Allergan, discusses two new potential ...

Age Related Macular Degeneration (AMD) Market Growth Projection from 2018 to 202  AlgosOnline

The New Research Report on Global Age Related Macular Degeneration (AMD) Market till 2023 added by Market Study Report studies the current and ...

Pixium Vision awarded Galien Prize 2018 for research with PRIMA system  GlobeNewswire

Pixium Vision awarded Galien Prize 2018 for research with PRIMA system for dry AMD. Paris, France - December 13, 2018 - 7 AM CET - Pixium Vision ...

OSN's top news of the week  Healio

Here are the top stories of the past week on Healio.com/OSN:

Italy free to reimburse off-label Avastin, rules EU court  pharmaphorum

Novartis and Roche's battle to try to prevent prescribing of Roche's Avastin has been dealt a blow by the European Court of Justice.

KOD Catches Eyes, MRNS On Watch, Mark Your Calendar For AQST  Nasdaq

Gained 22.37% to close Thursday's trading at $9.30. The Company went public on the Nasdaq Global Market on October 4, 2018, offering its shares at a.

IBD 50 Stocks To Watch: A Base Among Biotech Stocks  Investor's Business Daily

Biotech stocks aren't exactly setting the world on fire as the stock market wades through a tough stretch. But a few, like Regeneron Pharmaceuticals (REGN), ...

Age-related Macular Degeneration Sales Market 2018 Trends, Applications, Types and Future Outlook Report 2025  Blue Bird Magazine

The newly made known Age-related Macular Degeneration Sales Market report provides production process is analysed with respect to various aspects like, ...

Eye Drug Continues to Drive Regeneron's Growth  GuruFocus.com

Eye Drug Continues to Drive Regeneron's Growth, Stocks: REGN,NVS,RHHBY,XTER:BAYN,IBB,RGNX,APLS,OPHT,AGN, release date:Dec 04, 2018.

This Rockville biotech is getting some help from Maryland, MoCo for its new HQ  Baltimore Business Journal

Rockville-based RegenxBio Inc. (NASDAQ: RGNX) locked in a new headquarters site about a month ago. Now more details have emerged about financial ...

FDA Approves Aflibercept sBLA for Wet Age-related Macular Degeneration  MD Magazine

The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for an aflibercept (Eylea) injection in patients with wet ...

How to spot age-related macular degeneration  The Guardian

Every day in the UK, nearly 200 people develop a condition that can lead to visual impairment or even blindness. How do you identify the symptoms and what's ...

KOD For The Long Haul, GMDA Turning Heads, TNDM Jumps On Analyst Upgrade  Nasdaq

The Company went public on the Nasdaq Global Market on October 4, 2018, offering its shares at a price of $10.00 each. The net loss for the third.

Researchers are one step closer to developing eye drops to treat age-related macular degeneration  Medical Xpress

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration ...

Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights  Citizentribune

PALO ALTO, Calif., Nov. 16, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel ...

Computers Found to Equal Humans in Diagnosing Age-Related Macular Degeneration  MD Magazine

Computers can do as well as clinicians in diagnosing age-related macular degeneration, say investigators who have developed tools based on artificial ...

Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy  P&T Community

CRANBURY, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced several key corporate events ...

Patients with Concurrent Cataracts, Wet AMD Safe to Undergo Cataract Surgery  MD Magazine

Most patients, whether or not they had preoperative fluid, saw improved BCVA post-surgery, and there were no significant differences in central subfield ...

Implant Poised to Transform Macular Degeneration Treatment  Medscape

A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the ...

Blindness: Macular Degeneration Implant Treatment  Healthline

Researchers say the implant process could eventually be a treatment for the loss of eyesight experienced by millions as they grow older.

Macular Degeneration: Stem Cells Restore Sight in Small Study  Medscape

Doctors in the UK say they have taken an important step towards treating a common form of blindness – wet age-related macular degeneration (AMD).

Drug Pipeline for Macular Degeneration in Focus at AAO  Medscape

CHICAGO — New treatments for neovascular age-related macular degeneration and innovations in refractive surgery techniques will figure prominently at the ...

North East NHS bosses continue fight for cheaper anti-blindness drug despite objections  Chronicle Live

NHS bosses say they will press ahead with plans to roll out a cheaper anti-blindness drug, despite a bid by two pharma giants to overturn the court ruling that ...

Treat-Extend-Stop Protocol for Wet AMD: Long-term Outcomes  Medscape

A retrospective study finds that a treat-extend-stop protocol using anti-VEGF agents for neovascular age-related macular degeneration is associated with ...

Revolutionary eye drops to treat age-related macular degeneration  Drug Target Review

Revolutionary eye drops to treat age-related macular degeneration - developing an eye drop that could revolutionise treatment for AMD.

Roche's Faricimab Shows Long-Term Durability in Macular Degeneration  BioSpace

Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of ...

Stem cells treat macular degeneration  Medical Xpress

In July 2015, 86-year-old Douglas Waters developed severe age-related macular degeneration (AMD). He struggled to see things clearly, even when up close.

Hope for new treatments buoys macular degeneration patients  The Boston Globe

Scientists are experimenting with dozens of new treatments, including about 20 in clinical trials, to combat an eye disease that afflicts more than 9 million ...

Ophthotech (OPHT) Down 21.7% Since Last Earnings Report: Can It Rebound?  Zacks.com

Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To Pit It Against A Host Of Competitors  Seeking Alpha

Allergan and Molecular Partners achieve positive results in two phase 3 studies using abicipar for treating patients with wet age-related macular degeneration.

RGX-314 Gene Therapy for Wet AMD Well Tolerated at 24 Weeks  MD Magazine

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months ...

Novartis and Bayer to fight 'unlawful' UK court judgment allowing new AMD treatment  Insight News

Pharmaceutical giants Novartis and Bayer are fighting a landmark court judgment allowing UK doctors to offer an unlicensed treatment that competes with their ...

Adverum Biotechnologies receives fast track designation for wet AMD therapy  Healio

The FDA granted fast track designation for ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration, according to a ...

Patient Voices: Macular Degeneration  New York Times

Five men and women speak about their lives with progressive vision loss.

Regenxbio completes dosing in phase 1 trial of gene therapy for wet AMD  Healio

Dosing is complete in a phase 1 clinical trial of RGX-314, a gene therapy treatment for wet age-related macular degeneration, according to a press release from ...

Ask the Expert: Macular degeneration can lead to difficulty reading, recognizing faces and performing other fine tasks  Baltimore Sun

Macular degeneration is a disease of the eye that doesn't lead to total blindness, but in its advanced stages can cause blind areas. This can make it hard for ...

TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting  GlobeNewswire

SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the ...

Insomnia Linked to Increased Risk of Developing AMD  MD Magazine

Not sleeping can lead to more than just tired eyes—insomnia has been identified as an objective sign of an increased risk of developing age-related macular ...

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the Speculative Spotlight  FDA Headlines

Dec 7, 2018 | Business. Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Could be Ready to Star in the. Regeneron Pharmaceuticals Inc ...

NHS Wins High Court Case Over Avastin for Wet AMD  Medscape

NHS CCGs in the north east of England have fought off a High Court challenge to the prescribing of bevacizumab (Avastin) for wet age-related macular ...

Port Delivery System Proves Effective for Patients with Wet AMD in LADDER Trial  MD Magazine

Positive top-line results from the phase 2 LADDER study, which evaluated the safety and efficacy of an investigational Port Delivery System with ranibizumab ...

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Associated Press

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 27, 2018--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...

Ophthotech (OPHT) Upgraded at Zacks Investment Research  XNewsPress

Zacks Investment Research upgraded shares of Ophthotech (NASDAQ:OPHT) from a sell rating to a hold rating in a research report released on Tuesday ...

OCT Angiography Predicts Exudation in Macular Degeneration  Medscape

Optical coherence tomography (OCT) angiography can predict progression of age-related macular degeneration and identify which patients might benefit from ...

Implantable Ranibizumab Port for Wet AMD Lasts Up to 15 Months  MD Magazine

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 ...

RegenXBio Gene Therapy Shows Early Promise For Eye Disease; Cholesterol Treatment Results Mixed  Forbes

A gene therapy being developed by RegenX Bio of Rockville, MD, showed early promise against wet macular degeneration, a leading cause of blindness.

Ophthotech Corporation (OPHT) Plunges 8.24% on December 11  Equities.com

Ophthotech Corporation is a Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye.

Macular Degeneration: Managing This Vision Condition  U.S. News & World Report

Helyn Guerry, 88, of Houston, looks around her room but struggles to make out the objects directly in front of her. Macular degeneration, a common eye condition ...

Don't let macular degeneration get in the way of your life  The Grand Junction Daily Sentinel

It's a dewy morning in the forest as you and your partner make your way through the weekend hike. You're enjoying the sounds of nature but having trouble ...

Reviewing Akebia Therapeutics (AKBA) and OHR Pharmaceutical (OHRP)  Fairfield Current

Akebia Therapeutics (NASDAQ:AKBA) and OHR Pharmaceutical (NASDAQ:OHRP) are both small-cap medical companies, but which is the better investment?

Stem Cells Show Promise For Macular Degeneration  WebMD

A new stem cell transplant might help preserve or even restore vision being lost to the dry form of age-related macular degeneration.

Ophthotech (OPHT) Upgraded to “Hold” at Zacks Investment Research  Fairfield Current

Zacks Investment Research upgraded shares of Ophthotech (NASDAQ:OPHT) from a sell rating to a hold rating in a report issued on Tuesday morning.

Novartis challenges court ruling allowing use of Avastin in wet AMD  pharmaphorum

Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche's Avastin in an unlicensed use in wet AMD.

Adverum Biotechnologies Inc (ADVM) Receives $5.13 Average PT from Analysts  Fairfield Current

Adverum Biotechnologies Inc (NASDAQ:ADVM) has earned an average rating of “Hold” from the eight research firms that are presently covering the stock, ...

First Republic Investment Management Inc. Reduces Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

First Republic Investment Management Inc. decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.6% during the 3rd quarter, ...

First patients in Europe, Israel enrolled in Opthea wet AMD phase 2b study  Healio

The first patients in Europe and Israel have been dosed in a phase 2b study of Opthea's OPT-302 for wet age-related macular degeneration, according to a ...

Malaria Drug Amodiaquine Improves Blood Vessel Growth in AMD  MD Magazine

In animal models, not only did the drug help protect apelin function-deficient models from laser-induced choroidal neovascularization, but it did it through unique ...

Reducing Treatment Burden in Neovascular Age-related Macular Degeneration: What's Now? What's Next?  Healio

Education Lab | Neovascular, or “wet” age-related macular degeneration (nAMD) imposes a high burden on patients and eye care providers alike, as optimal ...

Treat-and-extend with ranibizumab comparable to monthly treatment for wet AMD  Healio

VANCOUVER, British Columbia — A 24-month treat-and-extend analysis trial with ranibizumab for patients with neovascular age-related macular degeneration ...

Brolucizumab meets secondary endpoints for fluid resolution in wet AMD  Healio

A new data analysis of prespecified secondary endpoints of the phase 3 HAWK and HARRIER trials showed that retinal fluid was detected less often in patients ...

Phase 3 trials to focus on Port Delivery System for AMD, faricimab for DME  Healio

Genentech and Roche announced the initiation of three large phase 3 clinical trials evaluating the Port Delivery System with ranibizumab to treat wet ...

Implanting stem cell 'patch' can restore vision  Futurity: Research News

Clinical trial results show that a stem cell patch can treat sudden, severe sight loss due to a form of macular degeneration.

Eye implant could more effectively prevent a common form of blindness  New Atlas

Age-related macular degeneration (AMD) is one of the leading causes of blindness in older people, with the "wet" form of the disease being responsible for ...

Potential New Drug Target for Age-Related Macular Degeneration Identified  MD Magazine

Those with the AMD showed greater expression of miRNA-150 than those without, offering evidence that miRNA-150 could be used as a potential ...

Has UVa Found a Cure for Macular Degeneration?  WMRA Public Radio

Macular degeneration may not get as much attention as Alzheimer's disease or breast cancer, but nearly one-third of people over 80 are affected by it. One.

New Stem Cell Treatment Reverses Vision Loss in 2 Patients  Live Science

Two people who were going blind can now see the word in much greater detail than before thanks to an experimental stem cell treatment for macular ...

A Daily Orange May Reduce AMD Risk, Study Finds  Medscape

People who consume at least one orange per day have a 60% lower risk of developing age-related macular degeneration (AMD) 15 years later compared with ...

Kodiak Sciences Files for IPO to Fund Global AMD Eye-Drug Studies  Xconomy

Many patients with the more severe form of age-related macular degeneration, a type of vision loss, have trouble with the standard treatment---a.

Is Age-Related Macular Degeneration Declining?  Medscape

An aging population should mean an uptick in age-related macular degeneration cases, but recent data suggest that is not what's happening.

Eating leafy greens could help prevent macular degeneration  Science Daily

A new study has shown that eating vegetable nitrates, found mainly in green leafy vegetables and beetroot, could help reduce your risk of developing ...

Initiation and maintenance of a Treat-and-Extend regimen for ranibizum | OPTH  Dove Medical Press

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK ...

ENZON PHARMACEUTICALS INC (OTCMKTS:ENZN) Sellers Strengthened By 505.88% Their Shorts  The EN Bulletin

Change of 505.88% for ENZON PHARMACEUTICALS INC (OTCMKTS:ENZN)'s short interest was reported. It was published in December by FINRA the 10300 ...

Wet Macular Degeneration Market 2018 Pipeline Insight and Forecast Report  TokensJournal

The Wet Macular Degeneration Market – Pipeline Insight report delivers comprehensive attention of the pipeline landscape for this mechanism of action, ...

Mediterranean diet prevents a leading cause of blindness, study suggests: Research shows we can all eat our way to better eye health  Science Daily

Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD), a leading cause of blindness in ...

The vision thing: stem cell procedures produce stunning  Cosmos

Two clinical trials return better-than-predicted results, raising hopes for widespread blindness treatment. Elizabeth Finkel reports.

Why Private Equity Has Eyes On Vision Care  Law360

With an aging population, significant cash-based premium business opportunities and a highly fragmented industry, the optical care space should continue ...

CCGs win right to offer patients Avastin for wet AMD  The BMJ

BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k4035 (Published 24 September 2018) Cite this as: BMJ 2018;362:k4035. Article; Related *content*; Metrics ...

Global Age Related Macular Degeneration Market Forecast 2018-2023 Regeneron, Novartis, Valeant, Pfizer  thestocknewsnow.com

Global Age Related Macular Degeneration (AMD) Market Report 2018-2023, describes an in-depth evaluation and professional study on the present and future ...

Regenxbio's wet AMD gene therapy shows promise in phase 1  FierceBiotech

Regenxbio's gene therapy for wet age-related macular degeneration (AMD) reduced the need for in-eye injections of anti-VEGF drugs. The company is now ...

How Perceptions of High Drug Prices Do Not Necessarily Match Reality  BioSpace

The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, ...

Adverum Bio's gene therapy ADVM-022 shows positive action in preclinical wet AMD study  Seeking Alpha

Results from a preclinical study evaluating Adverum Biotechnologies' (ADVM -0.4%) gene therapy ADVM-022 in a non-human primate model of wet age-related ...

» Load more

What about Resources?

Dr. Pautler's Blog
American Academy of Ophthalmology
MedlinePlus
National Institutes of Health
  • ARMD
    NIH's SeniorHealth website covers the topic of Age-Related Macular Degeneration
National Eye Institute
American Foundation for the Blind - Senior Site
  • Macular Degeneration
    Basic information about AMD and low vision; includes a self-test using an Amsler Grid
Journal of the American Medical Association (JAMA)
WebMD
LightHouse International
  • Macular Degeneration
    Provides a general overview of the basics of AMD, and a simulation showing a scene as it might be viewed by a person with AMD
Prevent Blindness America